A股異動丨科興製藥跌近9%,擬轉讓全資子公司同安醫藥100%股權
科興製藥(688136.SH)跌近9%,報51.4元,總市值102.6億元。科興製藥公告稱,公司擬將持有的全資子公司深圳同安醫藥有限公司(簡稱“同安醫藥”)100%的股權轉讓給廣西壯族自治區藥物研究所有限公司,轉讓價格爲1500萬元。科興製藥表示,同安醫藥系公司全資子公司,近年來未實際開展業務,其目前持有的藥品批件與公司目前的核心業務佈局等方面具有一定差異,後續如開展業務運營需要較長週期的投入與資源配置。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.